Comparison of methods for the prediction of human clearance from hepatocyte intrinsic clearance for a set of reference compounds and an external evaluation set

References

• Armitage P, Berry G. (1994). Statistical methods in medical research. 3rd ed. Oxford: Blackwell Scientific Publications
   Google Scholar
• Bonn B, Svanberg P, Janefeldt A, et al. (2016). Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRG. Drug Metab Dispos 44:527–33
   PubMed Web of Science ®Google Scholar
• Brandon EF, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–46
   PubMed Web of Science ®Google Scholar
• Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293–301
   PubMed Web of Science ®Google Scholar
• Camilleri M. (2008). Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 20:971–9
   PubMed Web of Science ®Google Scholar
• Chan TS, Yu H, Moore A, et al. (2013). Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024–32
   PubMed Web of Science ®Google Scholar
• Cook D, Brown D, Alexander R, et al. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:419–31
   PubMed Web of Science ®Google Scholar
• Dolgos H, Trusheim M, Gross D, et al. (2016). Translational medicine guide transforms drug development processes: the recent Merck experience. Drug Discov Today 21:517–26
   PubMed Web of Science ®Google Scholar
• Donato MT, Castell JV. (2003). Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 42:153–78
   PubMed Web of Science ®Google Scholar
• Grime K, Riley RJ. (2006). The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7:251–64
   PubMed Web of Science ®Google Scholar
• Hallifax D, Galetin A, Houston JB. (2008). Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 38:353–67
   PubMed Web of Science ®Google Scholar
• Hansch C, Leo A, Hoekman D. (1995). In exploring QSAR. hydrophobic, electronic and steric constants. Washington (DC): American Chemical Society
   Google Scholar
• Hewitt NJ, Lechón MJ, Houston JB, et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33
   PubMed Web of Science ®Google Scholar
• Hosey CM, Benet LZ. (2015). Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions. Mol Pharm 12:1456–66
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. (2004). Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 21:785–92
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. (2005). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103–12
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Gertz M, Houston JB, Galetin A. (2008). Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 36:1194–7
   PubMed Web of Science ®Google Scholar
• Kovar A, Peters T, Beier N, Derendorf H. (2001). Pharmacokinetic/pharmacodynamic evaluation of the NHE inhibitor eniporide. J Clin Pharmacol 41:139–48
   PubMed Web of Science ®Google Scholar
• Krösser S, Wolna P, Fischer TZ, et al. (2015). Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol 55:1051–60
   PubMed Web of Science ®Google Scholar
• Luzier A, Morse GD. (1993). Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res 21:267–80
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. (2004). Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247–53
   PubMed Web of Science ®Google Scholar
• Nordell P, Svanberg P, Bird J, Grime K. (2013). Predicting metabolic clearance for drugs that are actively transported into hepatocytes: incubational binding as a consequence of in vitro hepatocyte concentration is a key factor. Drug Metab Dispos 41:836–43
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
   PubMed Web of Science ®Google Scholar
• Poulin P, Haddad S. (2013). Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. J Pharm Sci 102:3239–51
   PubMed Web of Science ®Google Scholar
• Poulin P, Cornelis Hop ECA, Ho Q, et al. (2012a). Comparative assessment of in vitro–in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101:4308–26
   PubMed Web of Science ®Google Scholar
• Poulin P, Kenny JR, Eca H, Haddad S. (2012b). In vitro–in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing methods. J Pharm Sci 101:838–51
   PubMed Web of Science ®Google Scholar
• Ravandi F, Pigneux A, DeAngelo DJ, et al. (2015). Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J 5:e375
   PubMed Web of Science ®Google Scholar
• Richard B, Launay-Iliadis MC, Iliadis A, et al. (1992). Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. Br J Cancer 65:399–404
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304–11
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci 100:4090–110
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schänzle G, Bischoff D, Süssmuth RD. (2016). Upcyte human hepatocytes: a potent in vitro tool for the prediction of hepatic clearance of metabolically stable compounds. Drug Metab Dispos 44:435–44
   PubMed Web of Science ®Google Scholar
• Scheible H, Kraetzer F, Johne A, Wimmer E. (in manuscript). Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phospho ethanolamine in patients with solid tumors
   Google Scholar
• Soars MG, Grime K, Sproston JL, et al. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–65
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637–49
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Jones C, Ferguson D, et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841–53
   PubMed Web of Science ®Google Scholar
• Stringer R, Nicklin PL, Houston JB. (2008). Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313–29
   PubMed Web of Science ®Google Scholar
• Tang H, Hussain A, Leal M, et al. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–93
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabol Dispos 32:1201–8
   PubMed Web of Science ®Google Scholar